Clinical Trials Logo

Clinical Trial Summary

This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events

Clinical Trial Description

This was a multi-national, long-term safety study. Patients enrolled in study FTY720D2406 who experienced a cardiovascular event within 24-hours of fingolimod treatment initiation which led to overnight monitoring or met serious adverse event criteria, were eligible to participate in this study. Patients who experienced a qualifying event in study CFTY720D2406 started study CFTY720D2409 approximately 6 months after the occurrence of the CFTY720D2406 qualifying event. Patients underwent mandatory assessments on a 6-monthly basis including 12-lead ECG, vital signs. Other assessments were performed as per routine practice. The primary objective of the study was to estimate the long-term cardiovascular risk of fingolimod in patients who experienced a cardiovascular event during treatment initiation. The study has no stand-alone secondary objective. However data from the CFTY720D2409 and CFTY720D2406 studies will be pooled to supplement CFTY720DD2406 study and support its primary and secondary objectives of evaluating the safety profile of fingolimod. The pooled data will be appended to this result upon completion of FDA submission. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT02232061
Study type Interventional
Source Novartis
Status Completed
Phase Phase 4
Start date September 29, 2014
Completion date January 24, 2020

See also
  Status Clinical Trial Phase
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Recruiting NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Active, not recruiting NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4
Recruiting NCT03983681 - Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS N/A
Enrolling by invitation NCT04676204 - Relationship Between Oral DMT Burden and Adherence in MS
Recruiting NCT03424733 - Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects Phase 4
Active, not recruiting NCT03122652 - Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome Phase 3
Completed NCT03326505 - Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment Phase 1/Phase 2
Active, not recruiting NCT03396822 - Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Completed NCT04035889 - Melatonin for Sleep in MS N/A
Recruiting NCT03854123 - Multiple Sclerosis in the Elderly: Epidemiology, Clinical and MRI Characteristics
Active, not recruiting NCT03355365 - Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis Phase 2